08:54 AM EDT, 07/23/2025 (MT Newswires) -- Humacyte ( HUMA ) said Wednesday that it has sold its first sale of Symvess to a US military treatment facility serving around 200,000 active-duty personnel, retirees, and their families.

The company said the sale follows Symvess's recent listing on the US Defense Logistics Agency's ECAT system, enabling its access across 35 military treatment facilities and 160 US Department of Veterans Affairs hospitals.

Symvess received US FDA approval for treating extremity vascular trauma in December.

Shares of the company were up more than 7% in recent Wednesday premarket activity.